Did Abiomed and These Stocks Miss or Beat Analyst Expectations?

Abiomed Inc. (NASDAQ:ABMD) had a loss and missed Wall Street’s expectations, AND came up short on beating the revenue expectation. Adjusted Earnings Per Share decreased to $-0.04 in the quarter versus EPS of $0.08 in the year-earlier quarter. Revenue Rose 10.11% to $42.7 million from the year-earlier quarter.

Abiomed Inc. reported adjusted EPS loss of $0.04 per share. By that measure, the company missed the mean analyst estimate of $0.06. It missed the average revenue estimate of $42.93 million.

ABMD 20130803

Acorda Therapeutics, Inc. (NASDAQ:ACOR) delivered a profit and beat Wall Street’s expectations, AND beat the revenue expectation. Adjusted Earnings Per Share increased 127.27% to $0.25 in the quarter versus EPS of $0.11 in the year-earlier quarter. Revenue Rose 15.12% to $87.1 million from the year-earlier quarter.

Acorda Therapeutics, Inc. reported adjusted EPS income of $0.25 per share. By that measure, the company beat the mean analyst estimate of $0.09. It beat the average revenue estimate of $82.57 million.

ACOR 20130803

Addus HomeCare Corp. (NASDAQ:ADUS) delivered a profit and met Wall Street’s expectations, AND beat the revenue expectation. Adjusted Earnings Per Share increased 57.14% to $0.22 in the quarter versus EPS of $0.14 in the year-earlier quarter. Revenue Decreased 6.45% to $65.75 million from the year-earlier quarter.

Addus HomeCare Corp. reported adjusted EPS income of $0.22 per share. By that measure, the company missed the mean analyst estimate of $0.22. It beat the average revenue estimate of $63.26 million.

ADUS 20130803

AMN Healthcare Services Inc. (NYSE:AHS) delivered a profit and beat Wall Street’s expectations, AND beat the revenue expectation. Adjusted Earnings Per Share increased 63.64% to $0.18 in the quarter versus EPS of $0.11 in the year-earlier quarter. Revenue Rose 7.68% to $253.9 million from the year-earlier quarter.

AMN Healthcare Services Inc. reported adjusted EPS income of $0.18 per share. By that measure, the company beat the mean analyst estimate of $0.15. It beat the average revenue estimate of $253.68 million.

AHS 20130803

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) had a loss and beat Wall Street’s expectations, AND beat the revenue expectation. Adjusted Earnings Per Share decreased to $-0.09 in the quarter versus EPS of $0.15 in the year-earlier quarter. Revenue Decreased 36.79% to $19.6 million from the year-earlier quarter.

AMAG Pharmaceuticals, Inc. reported adjusted EPS loss of $0.09 per share. By that measure, the company beat the mean analyst estimate of $-0.17. It beat the average revenue estimate of $18.51 million.

AMGN 20130803

Stocks with improving earnings metrics are worthy of your extra attention. In fact, “E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our CHEAT SHEET investing framework for this very reason. Don’t waste another minute – click here and get our CHEAT SHEET stock picks now.